Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5843633

Title:Characterization of a human hematopoietic progenitor cell antigen
Inventors:Yin, Amy; San Jose, CA, USA
Summary:This invention introduces a human hematopoietic progenitor cell antigen which binds to an antibody produced by a specific hybridoma. Described herein is an antibody specific for the hematopoietic progenitor cell antigen AC133, and associated antibodies that specifically bind to the antigen, expression of which is described as being highly tissue-specific and detectable only on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. Further disclosed are properties of a subset of cells recognized by AC133, namely, CD34bright, and which contain substantially all of the CFU-GM activity present in the CD34+ population. Claims of the invention include a highly specific distribution of AC133 which makes it useful as a reagent for the isolation and characterization of human hematopoietic progenitor and stem cells. Also provided are methods by which cells selected for the expression of the AC133 antigen may be further purified by selection for other hematopoietic stem cell and progenitor cell markers. Therapeutic applications are included for the purification of cells for use as gene therapy vehicles and for bone marrow reconstitution.
Abstract:An hematopoietic progenitor cell antigen, and antibodies that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34.sup.bright, and contains substantially all of the CFU-GM activity present in the CD34.sup.+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen may be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5843633
Application Number:US1996000639891
Date Filed:26/04/1996
Date Published:01/12/1998
Assignee:Amcell Corporation, Sunnyvale, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021